Vical's CEO Presents At Bank Of America Merrill Lynch Health Care Conference Call (Transcript)

Vical Inc. (VICL)

Bank of America Merrill Lynch Health Care Conference Call

May 15, 2012 01:00 pm ET

Executives

Vijay B. Samant – President and Chief Executive Officer

Analysts

Rachel Mcminn – Bank of America Merrill Lynch

Presentation



Rachel Mcminn – Bank of America Merrill Lynch

Compare to:
Previous Statements by VICL
» Vical's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Vical's CEO Hosts at Citi 2012 Global Health Care Conference (Transcript)
» Vical's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Vical Incorporated at Credit Suisse Group Healthcare Conference Call Transcript

Okay, thanks very much everybody for joining us for our next presentation. My name is Rachel McMinn, I’m one of the biotech analyst here at Bank of America Merrill Lynch. It’s my pleasure to introduce our next speaker Vijay Samant, President and CEO of Vical and he’s been at Vical for 10 years, 10 years so long time I look forward to hearing the latest on the company.

Vijay B. Samant

Thank you, Rachel and thank you to Bank of America for inviting us to this conference. Before I begin my formal presentation, please refer to our Safe Harbor, I may be making some forward-looking statements. And please refer to our Q’s and K’s to fully understand the risk associated in investing in Vical.

For the members of the audience who don’t have a full understanding of Vical, Vical is a development stage drug company with strong pipeline a lead program is for treatment of Allovectin, treatment of melanoma. Allovectin is the lead program, we have a substantial franchise for treating CMV disease we have partnered that with Astellas.

And then we have an exciting preclinical program for Herpes Simplex 2, where nothing is really going on, but one out of three people in the U.S. are HSV-2 positive. We have number of partnerships with major pharma companies. We are one of the few companies in Southern California, which has a biological manufacturing facility and we have a strong balance sheet, plenty of cash and no debt.

1 2 3 Next › Last »